Intercept Pharmaceuticals (ICPT) – Research Analysts’ Recent Ratings Updates

Several analysts have recently updated their ratings and price targets for Intercept Pharmaceuticals (NASDAQ: ICPT):

  • 11/12/2019 – Intercept Pharmaceuticals had its price target lowered by analysts at UBS Group AG from $136.00 to $135.00. They now have a “buy” rating on the stock.
  • 11/6/2019 – Intercept Pharmaceuticals had its price target lowered by analysts at Royal Bank of Canada from $135.00 to $134.00. They now have an “outperform” rating on the stock.
  • 11/5/2019 – Intercept Pharmaceuticals had its “buy” rating reaffirmed by analysts at Wedbush. They now have a $243.00 price target on the stock.
  • 11/5/2019 – Intercept Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $150.00 price target on the stock.
  • 10/31/2019 – Intercept Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 10/21/2019 – Intercept Pharmaceuticals had its price target lowered by analysts at Raymond James from $148.00 to $147.00. They now have a “strong-buy” rating on the stock.
  • 10/18/2019 – Intercept Pharmaceuticals was given a new $125.00 price target on by analysts at Jefferies Financial Group Inc. They now have a “buy” rating on the stock.
  • 10/18/2019 – Intercept Pharmaceuticals had its price target lowered by analysts at Credit Suisse Group AG from $167.00 to $87.00.
  • 10/16/2019 – Intercept Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 10/14/2019 – Intercept Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. They now have a $63.00 price target on the stock. According to Zacks, “Intercept’s lead drug Ocaliva’s performance has been strong in the year so far. Management’s efforts to increase awareness about the label update of the drug in 2018 and expand sales force across the United States, thereafter, are yielding results. Solid growth in patient enrollment is likely to drive the company’s performance. Meanwhile, Intercept is working to expand the drug’s label in the promising NASH space. While the failure of Gilead’s late-stage study on selonsertib in patients suffering from compensated cirrhosis due to NASH puts Intercept ahead in the race, additional results from the REGENERATE study in NASH were mixed and did not impress investors. Nevertheless, a potential approval in this indication will significantly boost growth. However, shares have underperformed the industry in the year so far.”
  • 10/10/2019 – Intercept Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 10/4/2019 – Intercept Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 9/30/2019 – Intercept Pharmaceuticals was given a new $243.00 price target on by analysts at Wedbush. They now have a “buy” rating on the stock.
  • 9/27/2019 – Intercept Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

ICPT stock opened at $83.00 on Tuesday. The stock has a 50-day moving average price of $70.64 and a two-hundred day moving average price of $73.15. Intercept Pharmaceuticals Inc has a 12-month low of $56.76 and a 12-month high of $131.87. The company has a current ratio of 5.49, a quick ratio of 5.49 and a debt-to-equity ratio of 4.02. The company has a market cap of $2.72 billion, a PE ratio of -7.64 and a beta of 1.16.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($2.59) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($2.35) by ($0.24). Intercept Pharmaceuticals had a negative net margin of 143.09% and a negative return on equity of 495.47%. The firm had revenue of $61.95 million for the quarter, compared to analysts’ expectations of $63.89 million. During the same period last year, the firm posted ($2.18) EPS. Intercept Pharmaceuticals’s revenue was up 31.8% on a year-over-year basis. Equities analysts forecast that Intercept Pharmaceuticals Inc will post -10.11 EPS for the current fiscal year.

In related news, Director Srinivas Akkaraju bought 5,207 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The stock was bought at an average price of $60.32 per share, with a total value of $314,086.24. Following the completion of the transaction, the director now directly owns 21,526 shares of the company’s stock, valued at $1,298,448.32. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, General Counsel Ryan T. Sullivan sold 500 shares of the company’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $85.00, for a total value of $42,500.00. Following the completion of the sale, the general counsel now directly owns 26,929 shares of the company’s stock, valued at approximately $2,288,965. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,899 shares of company stock valued at $227,595. 5.00% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Larson Financial Group LLC boosted its position in shares of Intercept Pharmaceuticals by 2,916.7% in the third quarter. Larson Financial Group LLC now owns 543 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 525 shares during the period. Tower Research Capital LLC TRC purchased a new stake in shares of Intercept Pharmaceuticals in the third quarter worth about $36,000. First Mercantile Trust Co. purchased a new stake in shares of Intercept Pharmaceuticals in the third quarter worth about $37,000. Compagnie Lombard Odier SCmA purchased a new stake in shares of Intercept Pharmaceuticals in the second quarter worth about $80,000. Finally, NumerixS Investment Technologies Inc purchased a new stake in shares of Intercept Pharmaceuticals in the second quarter worth about $88,000. 81.82% of the stock is owned by institutional investors.

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

Featured Story: Why does a company issue an IPO?

Receive News & Ratings for Intercept Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.